Federal Register #2026-07770

Licensing Opportunity: NIAID Monoclonal Antibodies for West Nile Virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of NIH under HHS, is offering government-owned monoclonal antibody technologies for commercial licensing and collaborative research. - Government Buyer: - Department of Health and Human Services (HHS) - National Institutes of Health (NIH) - National Institute of Allergy and Infectious Diseases (NIAID) - OEMs and Technology Developers: - NIAID (government-owned inventions) - Collaborators: Sheba Medical Center, Israeli Ministry of Health - Products/Technologies Available for Licensing: - Seven fully human monoclonal antibodies targeting West Nile Virus (WNV) envelope protein: - AIS196, AIS204, AIS259, AIS260, AIS261, AIS262, AIS265 - Part number: E02120260 - Includes antibody sequences, engineered variants, and diagnostic applications - Technology supports development of full-length antibodies, fragments, and engineered versions for improved duration or immune modulation - Intended Uses: - Prevention or treatment of West Nile Virus infection, especially for high-risk populations - Diagnostic, surveillance, and research applications - Unique/Notable Requirements: - Available for commercial licensing and collaborative research - Intellectual property protected by provisional and PCT patent applications - No specific purchase quantities or product shipments; this is a technology licensing opportunity

Description

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), announces the availability for licensing of government-owned inventions. The notice highlights new fully human monoclonal antibodies against West Nile Virus (WNV) that strongly neutralize the virus and show protective effects in preclinical studies. These antibodies can be developed for prevention or treatment of WNV, especially for high-risk individuals, and may also be used in diagnostic and surveillance applications. The technology is available for commercial licensing and collaborative research opportunities to further develop and commercialize the invention.

View original listing